Reports of Radiotherapy and Oncology

Published by: Kowsar

Evaluation of Correlation Between Serum Level of Dihydropyrimidine Dehydrogenase Enzyme and Capecitabine Induced Adverse Reaction

Abolghasem Allahyari 1 , Maryam Sheikhvanloo 2 , Mahdi Jannati 2 , Fatemeh Kalalinia 3 , Amir Hoooshang Mohamadpoor 2 , 4 and Sepideh Elyasi 2 , *
Authors Information
1 Hematology-Oncology Department, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2 Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
3 Biotechnology Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran
4 Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Article information
  • Reports of Radiotherapy and Oncology: June 2017, 4 (1); e80910
  • Published Online: August 14, 2018
  • Article Type: Research Article
  • Received: June 16, 2018
  • Revised: July 21, 2018
  • Accepted: August 6, 2018
  • DOI: 10.5812/rro.80910

To Cite: Allahyari A, Sheikhvanloo M, Jannati M, Kalalinia F, Mohamadpoor A H, et al. Evaluation of Correlation Between Serum Level of Dihydropyrimidine Dehydrogenase Enzyme and Capecitabine Induced Adverse Reaction, Rep Radiother Oncol. 2017 ; 4(1):e80910. doi: 10.5812/rro.80910.

Copyright © 2018, Reports of Radiotherapy and Oncology. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Baan J, Bos MMEM, Gonesh-Kisoensingh SU, Meynaar IA, Alsma J, Meijer E, et al. Capecitabine-induced toxicity: an outcome study into drug safety. J Integr Oncology. 2014;3(1). doi: 10.4172/2329-6771.1000113.
  • 2. Walko CM, Lindley C. Capecitabine: a review. Clin Ther. 2005;27(1):23-44. doi: 10.1016/j.clinthera.2005.01.005. [PubMed: 15763604].
  • 3. Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol. 2012;13(6):579-88. doi: 10.1016/s1470-2045(12)70116-x.
  • 4. Morel A, Boisdron-Celle M, Fey L, Soulie P, Craipeau MC, Traore S, et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther. 2006;5(11):2895-904. doi: 10.1158/1535-7163.MCT-06-0327. [PubMed: 17121937].
  • 5. Salek R, Hosseini BA, Behravan J, Aledavood A, Sadeghi Ivari M. A survey on the prevalence of IVS14 + 1G > a mutation of the dihydropyrimidine dehydrogenase gene among a group of colorectal cancer patients in northeast iran, the relevance of fluoropyrimidine based chemotherapy toxicity. Rep Radiother Oncol. 2016;In Press(In Press). doi: 10.5812/rro.64853.
  • 6. Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in african-americans compared with caucasians. Clin Cancer Res. 2006;12(18):5491-5. doi: 10.1158/1078-0432.CCR-06-0747. [PubMed: 17000684].
  • 7. Dong QM, He YJ, Li S, Zhou ZM, Zhang L, Zhou ZW, et al. Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients. Aizheng/Chin J Cancer. 2005;24(4):483-7.
  • 8. National Cancer Institute. Common terminology criteria for adverse events V4.0 (CTCAE). 2013, [updated 2013]. Available from:
  • 9. Shields AF, Zalupski MM, Marshall JL, Meropol NJ. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. Cancer. 2004;100(3):531-7. doi: 10.1002/cncr.11925. [PubMed: 14745869].
  • 10. Saif MW, Katirtzoglou NA, Syrigos KN. Capecitabine: an overview of the side effects and their management. Anticancer Drugs. 2008;19(5):447-64. doi: 10.1097/CAD.0b013e3282f945aa. [PubMed: 18418212].
  • 11. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17(2):485-93. doi: 10.1200/JCO.1999.17.2.485. [PubMed: 10080589].
  • 12. Wang Y, Zhuang RY, Yu YY, Yu S, Hou J, Ji Y, et al. Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX). Oncotarget. 2016;7(46):76298-307. doi: 10.18632/oncotarget.11818. [PubMed: 27602586]. [PubMed Central: PMC5342815].
  • 13. van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res. 2000;6(12):4705-12. [PubMed: 11156223].
  • 14. Saif MW. Dihydropyrimidine dehydrogenase gene (DPYD) polymorphism among Caucasian and non-Caucasian patients with 5-FU- and capecitabine-related toxicity using full sequencing of DPYD. Cancer Genomics Proteomics. 2013;10(2):89-92. [PubMed: 23603345].
  • 15. Ciccolini J, Mercier C, Dahan L, Evrard A, Boyer JC, Richard K, et al. Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency. Cancer Chemother Pharmacol. 2006;58(2):272-5. doi: 10.1007/s00280-005-0139-8. [PubMed: 16292536].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments